Molecular epidemiology of hepatitis B virus

Korean Journal of Internal Medicine

Volumn 26, Issue 3, 2011, Pages 255-261

  Kao, Jia Horng ^a,b  

^a Hepatitis Research Center   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiviral agents; Genotype; Hepatitis B virus; Hepatocellular carcinoma; Molecular epidemiology

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE; TENOFOVIR DISOPROXIL;

ARTICLE; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE SEQUENCE; GENOMICS; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PATHOGENESIS; PREVALENCE; RISK FACTOR; SEROCONVERSION; TREATMENT RESPONSE; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MOLECULAR EPIDEMIOLOGY; PHENOTYPE; PROGNOSIS;

EID: 80054855341     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2011.26.3.255     Document Type: Article

References (42)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403.
2. Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res 2010;108:21-72.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-352.
4. Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993;342:1335-1340.
5. Kao JH. Hepatitis B viral genotypes: clinical relevance and mo- lecular characteristics. J Gastroenterol Hepatol 2002;17:643-650.
6. Kurbanov F, Tanaka Y, Mizokami M. Geographical and ge- netic diversity of the human hepatitis B virus. Hepatol Res 2010;40:14-30.
7. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008;15:137-145.
8. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 2011;26 Suppl 1:123-130.
9. Kao JH, Chen DS. HBV genotypes: epidemiology and implications regarding natural history. Curr Hepat Rep 2006;5:5-13.
10. Datta S. An overview of molecular epidemiology of hepatitis B virus (HBV) in India. Virol J 2008;5:156.
11. Phung TB, Alestig E, Nguyen TL, Hannoun C, Lindh M. Geno-type X/C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam: genotypes B4 and C1 predominate. J Med Virol 2010;82:1327-1333.
12. Tatematsu K, Tanaka Y, Kurbanov F, et al. A genetic variant of hepatitis B virus divergent from known human and ape geno-types isolated from a Japanese patient and provisionally as- signed to new genotype J. J Virol 2009;83:10538-10547.
13. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009;3:334-342.
14. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-1143.
15. Chen JD, Liu CJ, Lee PH, et al. Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2004;2:64-71.
16. Lin CL, Chen JD, Liu CJ, et al. Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. J Viral Hepat 2007;14:64-69.
17. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848-1856.
18. Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007;195:5-11.
19. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28:2437-2444.
20. Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006;44:915-924.
21. Liu CJ, Jeng YM, Chen CL, et al. Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B. J Infect Dis 2009;199:742-749.
22. Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core re- gions of hepatitis B virus. J Gastroenterol Hepatol 2003;18:630-637.
23. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25:1097-1107.
24. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008;13:613-624.
25. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
26. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005;54:1009-1013.
27. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e anti-gen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
28. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
29. Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007;44:541-548.
30. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.
31. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroen- terol 2006;101:297-303.
32. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-467.
33. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-2179.e1-e4.
34. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009;14:1183-1188.
35. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008;13:211-220.
36. Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 2010;52:441-449.
37. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-2009.
38. Hsieh TH, Tseng TC, Liu CJ, et al. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir Ther 2009;14:1157-1163.
39. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
40. Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 2007;1:415-430.
41. Kao JH. Appropriate use of interferon for treatment of chronic hepatitis B. Hepatol Res 2007;37(s1):S47-S54.
42. Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat 2010;17:601-610.